Allison Bratzel
Stock Analyst at Piper Sandler
(1.95)
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REPL Replimune Group | Maintains: Overweight | 14 22 | 9.31 | 136.31% | 2 | Jun 2, 2025 | |
TYRA Tyra Biosciences | Assumes: Overweight | 33 | 9.16 | 260.26% | 1 | May 21, 2025 | |
RARE Ultragenyx Pharmaceu... | Maintains: Overweight | 140 115 | 36.51 | 214.98% | 1 | Mar 17, 2025 | |
AKBA Akebia Therapeutics | Maintains: Overweight | 4 6 | 3.65 | 64.38% | 1 | Mar 14, 2025 | |
INZY Inozyme Pharma | Maintains: Overweight | 30 23 | 4 | 475% | 1 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 26 | 3.66 | 610.38% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 620 725 | 559.65 | 29.55% | 13 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 22 | 14.76 | 49.05% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 23 | 19.51 | 17.89% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 62 | 39.83 | 55.66% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 42 | 35.76 | 17.45% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 11.41 | 92.81% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 2.12 | 88.68% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 4.73 | 322.83% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 3.6 | 455.56% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 68.36 | 46.28% | 2 | Feb 8, 2023 |